• Alias: Farnesylthiosalicylic acid; FTS; ONO-7056; KD-032
    • A salicylic acid derivative that dislodges all RAS isoforms from their membrane-anchoring sites, thereby preventing the activation of RAS signaling cascades
    • Currently no active trials in the United States
    • Recommended phase 2 dose: 600 to 800 mg PO b.i.d. for 21 days, 7 days off
    • Half-life: 3.6 hours
    • Common side effects: Diarrhea, nausea/vomiting, fatigue, abdominal pain
    (Tsimberidou et al., 2010)
    Other topics in Targeted and Immunotherapy Agents